Market Capitalization Comparison for NovoNordisk and Eli Lilly Over the Last 5 Years

Pharma Giants' Market Cap Soars Over 5 Years

__timestampEli Lilly and CompanyNovo Nordisk A/S
Wednesday, January 1, 2020153244924560992801077492.3201
Friday, January 1, 2021250521319860.000031681508787391.9998
Saturday, January 1, 20223298910982402129286754102.3198
Sunday, January 1, 2023524266006679.999943131247795972.8003
Loading chart...

Unleashing insights

Market Capitalization: A Tale of Two Giants

In the past five years, the pharmaceutical titans Eli Lilly and Novo Nordisk have showcased remarkable growth in market capitalization. As of 2023, Novo Nordisk's market cap surged by an impressive 243% from its 2019 value, reaching a staggering 3.1 trillion. Meanwhile, Eli Lilly experienced a robust 330% increase, climbing to 527 billion. This growth reflects the companies' strategic innovations and expanding influence in the global healthcare sector. While Novo Nordisk leads with a market cap nearly six times that of Eli Lilly, both companies have demonstrated resilience and adaptability in a rapidly evolving market. Investors and industry watchers should keep a keen eye on these powerhouses as they continue to shape the future of pharmaceuticals.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
9 Dec 2024